Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder

Highlights • This meta-analysis confirms a robust link between IL-6, CRP and major depression.• The role of TNF-α and IL-1β in major depression remains uncertain.• Further mechanistic and immunotherapeutic studies on IL-6 and CRP are needed.

[1]  R. Bonsall,et al.  Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression , 2010, Biological Psychology.

[2]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[3]  P. Scully,et al.  Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression , 2005, Psychological Medicine.

[4]  J. Amsterdam,et al.  Positive and negative acute phase proteins in affective subtypes. , 1998, Journal of affective disorders.

[5]  M. Irwin,et al.  Depressive disorders and immunity: 20 years of progress and discovery , 2007, Brain, Behavior, and Immunity.

[6]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[7]  M. Kubera,et al.  Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  M. Maes,et al.  Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. , 2012, Journal of affective disorders.

[9]  A. Baker,et al.  Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis , 2012, Psychological Medicine.

[10]  H. Meltzer,et al.  Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression , 1995, European Archives of Psychiatry and Clinical Neuroscience.

[11]  C. Pariante,et al.  The role of immune genes in the association between depression and inflammation: A review of recent clinical studies , 2013, Brain, Behavior, and Immunity.

[12]  A. Siracusano,et al.  Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. , 2006, The Journal of clinical psychiatry.

[13]  W. Drevets,et al.  Sustained Low-Grade Pro-inflammatory State in Unmedicated, Remitted Women with Major Depressive Disorder as Evidenced by Elevated Serum Levels of the Acute Phase Proteins C-reactive Protein and Serum Amyloid A , 2007, Biological Psychiatry.

[14]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[15]  M. E. Hernández,et al.  Effect of Selective Serotonin Reuptake Inhibitors and Immunomodulator on Cytokines Levels: An Alternative Therapy for Patients with Major Depressive Disorder , 2013, Clinical & developmental immunology.

[16]  M. Irwin,et al.  Inflammatory Markers and Sleep Disturbance in Major Depression , 2005, Psychosomatic medicine.

[17]  N. Brandon,et al.  Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes , 2012, Translational Psychiatry.

[18]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[19]  M. E. Hernández,et al.  Th2 cytokine response in Major Depressive Disorder patients before treatment , 2006, Journal of Neuroimmunology.

[20]  A. Damjanović,et al.  Melancholic and atypical major depression — Connection between cytokines, psychopathology and treatment , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  M. Fasshauer,et al.  Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. , 2014, Journal of psychiatric research.

[22]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[23]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. , 2008, Progress in neuro-psychopharmacology & biological psychiatry.

[25]  M G Marmot,et al.  Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study , 2008, Psychological Medicine.

[26]  O. Forlenza,et al.  Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[27]  H. V. van Hout,et al.  Depression and the risk for cardiovascular diseases: systematic review and meta analysis , 2007, International journal of geriatric psychiatry.

[28]  R. S. Smith.  The macrophage theory of depression. , 1991, Medical hypotheses.

[29]  O. Mors,et al.  Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. , 2014, JAMA psychiatry.

[30]  E. Shevach,et al.  Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy , 2008, Clinical & developmental immunology.

[31]  A. Baker,et al.  A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: Exploring the causes of heterogeneity , 2012, Brain, Behavior, and Immunity.

[32]  V. Arolt,et al.  Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. , 2005, Journal of affective disorders.

[33]  M. Bloch,et al.  The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis , 2011, Neuropsychopharmacology.

[34]  B. Baune,et al.  Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity , 2012, Neuroscience & Biobehavioral Reviews.

[35]  Klaus P. Ebmeier,et al.  Interleukin-6 as a predictor of symptom resolution in psychological distress: a cohort study , 2015, Psychological Medicine.

[36]  J. Tímár,et al.  Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul , 2009, Molecular Psychiatry.

[37]  K. Hashimoto,et al.  Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression , 2015, Biological Psychiatry.

[38]  B. Nordestgaard,et al.  Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. , 2013, JAMA psychiatry.

[39]  W. Banks,et al.  Penetration of interleukin-6 across the murine blood-brain barrier , 1994, Neuroscience Letters.

[40]  R. Grassi‐Oliveira,et al.  Increased soluble tumor necrosis factor‐α receptors in patients with major depressive disorder , 2009, Psychiatry and clinical neurosciences.

[41]  A. Kersting,et al.  Inflammatory markers in major depression and melancholia. , 2001, Journal of affective disorders.

[42]  Chen Zhang,et al.  Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: A prospective longitudinal study , 2013, Psychoneuroendocrinology.

[43]  E. Göka,et al.  IL‐6 levels decrease with SSRI treatment in patients with major depression , 2005, Human psychopharmacology.

[44]  Alan J. Thomas,et al.  Increase in interleukin-1beta in late-life depression. , 2005, The American journal of psychiatry.

[45]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[46]  Tetsuya Takahashi,et al.  Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[47]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[48]  H. Meltzer,et al.  Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. , 1995, Journal of affective disorders.

[49]  Teresa A. Victor,et al.  Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities , 2013, Brain, Behavior, and Immunity.

[50]  F. Amico,et al.  Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation , 2012, Brain, Behavior, and Immunity.

[51]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[52]  Peter B. Jones,et al.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. , 2014, JAMA psychiatry.

[53]  S. Kéri,et al.  Expression of Toll-Like Receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder , 2014, Brain, Behavior, and Immunity.

[54]  Klaus P. Ebmeier,et al.  Long-term inflammation increases risk of common mental disorder: a cohort study , 2013, Molecular Psychiatry.

[55]  K. Kahl,et al.  Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression , 2014, Psychiatry Research.

[56]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[57]  R. Ader,et al.  Brain, behavior, and immunity , 1987, Brain, Behavior, and Immunity.

[58]  G. Juckel,et al.  New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atherosclerotic markers in patients with depression. , 2013, Journal of affective disorders.

[59]  B. Bondy,et al.  C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients. , 2008, Journal of psychiatric research.

[60]  S. Yamawaki,et al.  Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. , 2001, Neuropsychobiology.

[61]  G. Xie,et al.  Levels of Serum Interleukin (IL)-6, IL-1β, Tumour Necrosis Factor-α and Leptin and Their Correlation in Depression , 2007 .

[62]  R. Dantzer.  Cytokine-Induced Sickness Behavior: Where Do We Stand? , 2001, Brain, Behavior, and Immunity.

[63]  A. Serretti,et al.  Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features , 2012, Psychiatry Research.

[64]  M. H. Pollack,et al.  A detailed examination of cytokine abnormalities in Major Depressive Disorder , 2008, European Neuropsychopharmacology.

[65]  R. Ho,et al.  Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of Affective Disorders.

[66]  E. Maron,et al.  Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. , 2009, Medicina.

[67]  Michael Maes,et al.  Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[68]  J. Sinacore,et al.  Pro-inflammatory biomakers in depression: Treatment with venlafaxine , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[69]  H. Vedder,et al.  Cytokine Production and Treatment Response in Major Depressive Disorder , 2000, Neuropsychopharmacology.

[70]  I. Craig,et al.  Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors' and Longitudinal ‘Targets' , 2012, Neuropsychopharmacology.

[71]  M. Fornaro,et al.  Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. , 2013, Journal of affective disorders.

[72]  P. Joyce,et al.  Elevated levels of acute phase plasma proteins in major depression , 1992, Biological Psychiatry.

[73]  T. Vos,et al.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.

[74]  G. Xie,et al.  Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. , 2007, The Australian and New Zealand journal of psychiatry.

[75]  K. Malone,et al.  SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER , 2013, Depression and anxiety.

[76]  R. Lanius,et al.  Association of trauma exposure with proinflammatory activity: a transdiagnostic meta-analysis , 2014, Translational Psychiatry.

[77]  Chien-Te Lee,et al.  T‐helper 1/T‐helper 2 cytokine imbalance and clinical phenotypes of acute‐phase major depression , 2007, Psychiatry and clinical neurosciences.

[78]  O. Andreassen,et al.  The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery , 2014, Psychoneuroendocrinology.

[79]  M. Irwin,et al.  Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder , 2006, Brain, Behavior, and Immunity.

[80]  Alan J. Thomas,et al.  Increase in interleukin-1 beta in late-life depression , 2005 .

[81]  M. E. Hernández,et al.  Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder , 2008, European Neuropsychopharmacology.

[82]  E. Bosmans,et al.  Indicators of immune activation in major depression , 1996, Psychiatry Research.

[83]  S. Yamawaki,et al.  Plasma Concentrations of Interleukin-1β, Interleukin-6, Soluble Interleukin-2 Receptor and Tumor Necrosis Factor α of Depressed Patients in Japan , 2001, Neuropsychobiology.

[84]  T. Hoshuyama,et al.  Plasma levels of brain‐derived neurotrophic factor and interleukin‐6 in patients with dysthymic disorder: comparison with age‐ and sex‐matched major depressed patients and healthy controls , 2010, Human psychopharmacology.

[85]  O. Çalıyurt,et al.  Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder , 2003, Psychopharmacology.

[86]  E. Wright,et al.  Plasma CRP Levels in Premenopausal Women with Major Depression: A 12-Month Controlled Study , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[87]  W. Rief,et al.  Exercise affects symptom severity but not biological measures in depression and somatization – Results on IL-6, neopterin, tryptophan, kynurenine and 5-HIAA , 2013, Psychiatry Research.

[88]  E. Bosmans,et al.  Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis , 2001, European Neuropsychopharmacology.

[89]  P. Gass,et al.  IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors , 2006, Neurobiology of Disease.

[90]  Mike Clarke,et al.  Accumulating Research: A Systematic Account of How Cumulative Meta-Analyses Would Have Provided Knowledge, Improved Health, Reduced Harm and Saved Resources , 2014, PloS one.

[91]  W. Rief,et al.  Depression, cytokines and experimental pain: evidence for sex-related association patterns. , 2011, Journal of affective disorders.

[92]  Theo Stijnen,et al.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. , 2010, Archives of general psychiatry.

[93]  Klaus P. Ebmeier,et al.  CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. , 2013, Journal of affective disorders.

[94]  O. Wolkowitz,et al.  Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. , 2009, Journal of psychiatric research.

[95]  G. Perugi,et al.  Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation , 2011, Neuropsychiatric disease and treatment.

[96]  C. Pariante,et al.  Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. , 2013, Journal of affective disorders.

[97]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[98]  O. Forlenza,et al.  Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. , 2010, Journal of psychiatric research.

[99]  P. Scully,et al.  Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. , 2007, Journal of psychiatric research.

[100]  B. Feige,et al.  Effects of sleep deprivation on nocturnal cytokine concentrations in depressed patients and healthy control subjects. , 2012, The Journal of neuropsychiatry and clinical neurosciences.

[101]  N. Skokauskas,et al.  Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder , 2012, Translational Psychiatry.